Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Introduction: Streptococcus pneumoniae can cause serious invasive pneumococcal disease (IPD), such as pneumonia, meningitis and bactaeremia. Two pneumococcal polysaccharide conjugate vaccines (PCV), the 13-valent PCV13 and 10-valent PHiD-CV, are included in the Philippines' National Formulary and implemented in the national immunisation programme. Recently, a new 10-valent PCV (PCV10-SII) has received World Health Organization prequalification status. The objective of this study was to assess cost-effectiveness of the two 10-valent PCVs versus no vaccination and the relative cost-effectiveness of the two vaccines.
Methods: An existing Markov model was adapted to the Philippines context. Health outcomes, including bacteraemia, meningitis, pneumonia, acute otitis media (AOM), sequelae and death, were evaluated over a 5-year horizon without discounting. Quality-adjusted life years (QALYs) and costs were calculated over a lifetime horizon, applying a discount rate of 3.66%. The price of PCV10-SII was assumed to be 20% below the PHiD-CV market price; this price reduction was varied between 5% and 15% in scenario analyses.
Results: Both vaccination strategies dominated the 'no vaccination' strategy, producing more health benefits at lower total costs. The incremental cost-effectiveness ratio of PHiD-CV versus PCV10-SII was 54,553 Philippine pesos (PHPs) per QALY gained in the base case analysis. Vaccination with PHiD-CV was predicted to yield more QALYs compared with PCV10-SII (ΔQALY: 2929) since more cases of meningitis, bactaeremia and AOM were prevented but at higher direct costs due to the vaccine price difference. PHiD-CV would be the dominant option if the price reduction for PCV10-SII was at most 5%.
Conclusions: Both vaccination strategies are superior to no vaccination, producing more health benefits at lower costs. QALYs gained are higher with PHiD-CV but at higher direct costs. Results are most sensitive to assumptions about PCV10-SII vaccine price.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12271003 | PMC |
| http://dx.doi.org/10.1007/s40121-025-01162-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Economic Evaluation of PHID-CV versus PCV10-SII Compared with no Vaccination in the Philippines.
Infect Dis Ther
July 2025
GSK, Buenos Aires, Argentina.
Introduction: Streptococcus pneumoniae can cause serious invasive pneumococcal disease (IPD), such as pneumonia, meningitis and bactaeremia. Two pneumococcal polysaccharide conjugate vaccines (PCV), the 13-valent PCV13 and 10-valent PHiD-CV, are included in the Philippines' National Formulary and implemented in the national immunisation programme. Recently, a new 10-valent PCV (PCV10-SII) has received World Health Organization prequalification status.
View Article and Find Full Text PDFIndirect Comparison of PCV20 Immunogenicity with PCV10 in Pediatric 3 + 1 and 2 + 1 Schedules.
Infect Dis Ther
May 2025
Pfizer Vaccines, 500 Arcola Road, Collegeville, PA, 19426, USA.
Introduction: The 20-valent pneumococcal conjugate vaccine (PCV20) was licensed for prevention of pneumococcal disease in infants and children on the basis of immunogenicity compared with PCV13. We aimed to evaluate PCV20 immunogenicity compared with PCV10 (Synflorix; PhiD-CV) because both vaccines demonstrated lower immunogenicity than PCV13. Nevertheless, PCV10 was highly effective against vaccine-serotype pneumococcal disease in post-licensure studies.
View Article and Find Full Text PDFA cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia.
Hum Vaccin Immunother
November 2022
GSK, Buenos Aires, Argentina.
Background: In response to the substantial clinical and economic burden of diseases caused by and non-typeable (NTHi) in Tunisia, the 10-valent pneumococcal non-typeable protein D conjugate vaccine (PHiD-CV) was recently introduced into the national immunization program. However, there has yet to be a full-scale health economic analysis comparing currently available pneumococcal conjugate vaccines (PCVs) in Tunisia.
Methods: A Markov model that simulated the disease processes of invasive pneumococcal disease (IPD), pneumonia, and acute otitis media (AOM) over a newborn cohort lifetime was used to evaluate the cost-effectiveness/utility of PHiD-CV and the 13-valent pneumococcal conjugate vaccine (PCV13) from payer's perspective, using 3% discounting.
Impact of pneumococcal conjugate vaccines on healthcare utilization and direct costs for otitis media in children ≤2 years of age in two Swedish regions.
Hum Vaccin Immunother
December 2022
GSK, Rockville, MD, USA.
Unlabelled: In Sweden, the 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in 2009 and replaced by the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) or the 13- valent PCV (PCV13) from late 2009. We assessed the impact of PCVs on rates of antibiotic prescribing, tympanostomy tube placement (TTP), and healthcare resource utilization and direct costs of physician- diagnosed otitis media/acute otitis media (OM) in children ≤2 years of age living in Skåne (PCV7 then PHiD- CV) or Västra Götalandsregionen (VGR; PCV7 then PCV13). Retrospective cohort study using linked patient- level data from national and regional (Skåne and VGR) healthcare databases in Sweden from July 1, 2005, to December 31, 2013 (NCT02742753).
View Article and Find Full Text PDFImmunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
Lancet Infect Dis
June 2021
PATH, Seattle, WA, USA.
Background: An affordable pneumococcal conjugate vaccine (PCV) is needed to ensure sustainable access in low-income and middle-income countries. This trial examined the immunogenicity and safety of a novel ten-valent PCV (SIIPL-PCV) containing serotypes 1, 5, 6A, 6B, 7F, 9V, 14, 19A, 19F, and 23F compared with the pneumococcal polysaccharide protein D-conjugate vaccine (PHiD-CV; Synflorix; GlaxoSmithKline; Brentford, UK).
Methods: In this single-centre, randomised, double-blind, phase 3, non-inferiority trial in The Gambia, healthy, PCV-naive infants aged 6-8 weeks were enrolled and assigned using permuted block randomisation to receive one of three lots of SIIPL-PCV or to PHiD-CV in a ratio of 2:2:2:3.